Guidelines for Management of Ovarian Cancer in the State of Qatar

Objectives

The guideline establishes national clinical standards for the diagnosis, staging, treatment, follow-up and supportive care of ovarian cancer in Qatar. Its central aims are to promote earlier diagnosis, optimise surgery and systemic treatment, achieve complete resection of macroscopic disease where feasible, preserve quality of life, and provide palliative care when cure is not possible.[1][2][3]

• Coordinate care across gynaecology, gynaecological oncology, medical and radiation oncology, surgery, radiology, pathology, laboratory services, nursing, pharmacy, medical genetics and palliative care.[4]
• Ensure timely referral, specialist assessment, multidisciplinary team review, diagnosis and treatment, including a 48-hour specialist assessment target for Urgent Suspected Cancer referrals, diagnosis within 14 days of specialist assessment, and first definitive treatment within 14 days of multidisciplinary confirmation.[5]
• Assess suspected ovarian cancer through clinical history, examination, laboratory testing, tumour markers, imaging, pathology review and consideration of hereditary risk.[6]
• Use the risk of malignancy index, incorporating ultrasound findings, menopausal status and cancer antigen 125 level, to triage patients, with a score of 250 or above requiring further management.[6]
• Apply accurate clinical, pathological and anatomical staging, including International Federation of Gynaecology and Obstetrics staging and consistent use of Tumour, Node, Metastasis principles where applicable.[7][8]
• Deliver stage-, histology-, response- and patient-centred management through surgery, chemotherapy, limited radiotherapy and supportive or palliative care, taking account of age, performance status, individual circumstances and fertility preferences.[9][10]
• Preserve fertility for appropriately selected patients with early-stage or low-risk disease, germ-cell tumours or borderline ovarian tumours while maintaining adequate staging and management of visible disease.[9][10][11]
• Use imaging to establish disease extent, assess operability and cytoreduction potential, guide treatment planning, evaluate response and investigate recurrence.[12][13]
• Support informed treatment choices by explaining available options, including no treatment, and the expected benefits and risks.[4][14]

Implementation

Implementation centres on specialist multidisciplinary team-led care, structured referral routes, documented treatment decisions and delivery through designated treatment centres and specialised services. The guideline was developed through a multidisciplinary process supported by Hamad Medical Corporation and the Supreme Council of Health, agreed through the gynae-oncology tumour board, consulted on with stakeholders, and approved by the National Cancer Committee for dissemination in Qatar.[4][2][3]

• Manage referrals through a multidisciplinary team coordinator, who circulates case lists, sets submission deadlines and supports preparation for meetings. Refer newly diagnosed patients before treatment and refer suspected, recurrent, progressive, metastatic, diagnostically uncertain or complex cases for multidisciplinary review.[15]
• Use referral pathways from Primary Healthcare Centres, Hamad Medical Corporation services, private providers, other cancer multidisciplinary teams and clinicians treating patients returning after overseas care.[16]
• Record the patient’s presentation, investigations, results and multidisciplinary treatment plan; validate and sign off decisions, upload the outcome proforma to the patient record, and communicate private-sector recommendations to the referring clinician.[15]
• Arrange urgent decisions through discussion by at least two core multidisciplinary members from different disciplines where a case cannot await the regular meeting, then document the recommendation and list the patient for subsequent review.[15]
• Link the gynaecological oncology multidisciplinary team to the Qatar gynaecological oncology Tumour Board through attendance by the lead clinician or a nominated core member.[15][16]
• Provide patients with access to an advanced clinical nurse specialist, psychological support and psychiatric services where appropriate, and offer entry to available clinical trials.[4]
• Use computed tomography for primary staging, advanced-disease assessment, response evaluation and recurrence assessment; use magnetic resonance imaging for indeterminate adnexal masses and selected staging issues; and use positron emission tomography-computed tomography selectively for uncertain disease extent or suspected recurrence.[12][13]
• Process surgical specimens under pathology standard operating procedures, ensure specialist gynaecological pathology review, and present cases at the multidisciplinary meeting before post-surgical management decisions.[7]
• Perform surgery for suspected ovarian cancer under a designated gynaecological oncologist in a treatment centre, using comprehensive staging and cytoreduction with the aim of no visible residual disease where achievable.[2][17]
• Govern ultra-radical, interval debulking, fertility-preserving and selected secondary cytoreductive surgery through specialist multidisciplinary assessment, informed patient choice and appropriately experienced surgical teams.[14][18]
• Use neoadjuvant chemotherapy followed by surgery when primary cytoreduction is unsuitable and diagnostic confirmation has been obtained; select systemic treatment according to disease setting, platinum-free interval, tumour characteristics, performance status and patient preference.[9][19][20]
• Undertake baseline imaging, laboratory investigations, tumour-marker assessment, renal-function assessment for platinum treatment and performance-status documentation before systemic therapy; monitor cancer antigen 125 at each cycle, image after cycles 3 and 6, and document toxicity at every visit.[21][19]
• Use radiotherapy principally for palliation or prevention of complications, with treatment plans peer reviewed and approved through planning systems involving the radiation oncologist, medical physicist and planner.[18][21]
• Follow patients according to stage, recurrence risk, symptoms and marker status, with more intensive review in the first two years and longer-term follow-up for higher-risk, recurrent or advanced disease.[11]
• Review the guideline after one year through the gynae-oncology tumour board to determine whether evidence changes require early updating. The source does not specify budgets, financing arrangements or a wider programme-level performance-monitoring framework.[1][3]

Monitoring & Evaluation

Monitoring and accountability are principally embedded in clinical documentation, multidisciplinary review, pathway timelines, treatment assessment and follow-up rather than in a unified programme-level performance framework. The guideline is subject to ongoing 12-month review, with the gynae-oncology tumour board scheduled to review it one year after publication for evidence changes that could require an early update.[1][3]

• Document multidisciplinary team (MDT) discussions, the agreed management plan, validation and sign-off in the patient record through an outcome proforma accessible to professionals involved in care, including the primary healthcare physician.[4][15]
• Report tumour board attendance in the MDT team’s annual report, linking participation in the Qatar gynaecological oncology Tumour Board to team-level reporting.[15][16]
• Monitor referral-pathway timeliness by seeing patients referred through the Urgent Suspected Cancer form within 48 hours, achieving definitive diagnosis within 14 days of specialist assessment for confirmed cancer, and commencing first definitive treatment within 14 days of MDT-confirmed diagnosis.[5]
• Use the risk of malignancy index, incorporating ultrasound findings, menopausal status and cancer antigen 125 level, as a referral-triage criterion; a score of 250 or above prompts referral for further management.[6]
• Record pathology findings including clinical history, macroscopic and microscopic features, tumour grade, capsule status and International Federation of Gynaecology and Obstetrics stage.[7]
• Apply consistent clinical and pathological staging using the International Federation of Gynaecology and Obstetrics and, where applicable, Tumour, Node, Metastasis systems.[7][8]
• Assess imaging response at a frequency corresponding to chemotherapy regimens, and use imaging to inform interval debulking, recurrent-disease baselines and salvage-surgery assessment.[13]
• Record the extent of disease before debulking surgery, residual disease after surgery, completeness of resection, and the size, number and location of any remaining lesions.[17]
• Assess response before interval debulking surgery using cancer antigen 125 and imaging, and assess candidacy for secondary cytoreduction using recurrence distribution, prior chemotherapy response, residual disease, imaging and ascites.[14][18]
• Review radiotherapy plans through dose-volume histograms, isodose distribution and beam parameters; obtain documented treatment-plan approval and complete intra-departmental peer review before treatment.[18][21]
• Monitor radiotherapy delivery through protocol-based imaging, typically daily cone-beam computed tomography, and weekly review of progress and toxicity.[21]
• Complete baseline imaging and laboratory investigations before systemic therapy, measure cancer antigen 125 before cycle 1 and at every cycle, repeat imaging after cycles 3 and 6, and document performance status at the start of every cycle.[21]
• Document toxicity at every treatment visit using severity grades from 0 to 5, and document reasons when chemotherapy is administered to patients with an Eastern Cooperative Oncology Group performance status above 3.[21][19]
• Monitor relapsed or persistent disease with rising cancer antigen 125 but non-measurable or low-volume disease through close clinical and imaging review rather than routinely initiating systemic therapy outside a clinical trial.[19][20]
• Follow Stage I disease every three months for two years and every four to six months from years three to five, with discharge at five years considered; follow Stage II or higher, high-risk or recurrent disease on the same initial schedule and then annually for life.[11]
• Tailor surveillance to recurrence risk, symptoms and initially elevated tumour markers, using history, examination, blood tests, relevant tumour markers, ultrasound, computed tomography when indicated and annual chest X-ray.[11]
• Follow patients receiving fertility-sparing surgery for Stage I borderline ovarian tumours for at least 10 years with transvaginal ultrasound of the remaining ovary.[2]

The source does not specify a consolidated national indicator set, audit methodology, surveillance database, outcome targets, sanctions, or wider accountability framework beyond these clinical, documentation and annual-reporting arrangements.[1][15][11][3]

Costing & Financing

No explicit costing, budget, financing source, resource allocation, funding gap, resource-mobilisation mechanism or economic assumption is specified for the ovarian cancer guideline or its implementation.[1][3]

• Require specialist multidisciplinary teams, designated treatment centres, imaging, pathology, surgery, systemic therapy, radiotherapy, clinical nursing, psychological support and genetic services, but do not attach financial values, funding responsibilities or budget lines to these resources.[4][6][9][18]
• Require specialised units and appropriately trained surgical professionals for ultra-radical procedures, without specifying capital, workforce, operating or training costs.[17][14]
• Require imaging and laboratory monitoring before and during treatment, including computed tomography, cancer antigen 125 testing, glomerular filtration-rate assessment and treatment-toxicity review, without stating reimbursement arrangements or affordability assumptions.[21][19]
• Provide for clinical trials where available, but do not identify trial funding, patient costs, sponsor contributions or other financing arrangements.[4][19]

Accordingly, the source provides no machine-readable financial items and does not permit calculation of treatment, diagnostic, staffing, infrastructure or follow-up costs.[1][22][3]